ENCELTO® Granted Permanent J-Code, Enhancing Access for Patients with Macular Telangiectasia Type 2

Neurotech Pharmaceuticals has announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J3403) to ENCELTO® (revakinagene taroretcellwey), effective October 1, 2025. This milestone is expected to significantly improve access to the first and only FDA-approved treatment for idiopathic macular telangiectasia type 2 (MacTel), a rare, vision-threatening retinal disease.

Improving Access Through Streamlined Reimbursement

With the introduction of J-code J3403, CMS has formalized the reimbursement process for ENCELTO, simplifying claims submission for ophthalmology practices and infusion centers. The code allows providers to more efficiently bill for and administer ENCELTO, helping to reduce administrative burden and support broader, faster patient access to this novel therapy.

For clinicians treating patients with MacTel, this permanent code ensures greater consistency in reimbursement, promoting easier integration of ENCELTO into routine clinical workflows.

ENCELTO was developed as a targeted therapy for idiopathic macular telangiectasia type 2, a progressive and rare retinal disease that leads to central vision loss in adults. As the only FDA-approved treatment for MacTel, ENCELTO addresses a significant unmet need in retinal care.

Leadership Perspective

Richard Small, CEO of Neurotech Pharmaceuticals, emphasized the impact of the J-code assignment:

“Receiving a permanent J-code in the United States supports our efforts to increase timely access to ENCELTO, the first and only FDA-approved treatment for MacTel. We are committed to making this important therapy available to patients in need.”